Vivosim Lab Inc (VIVS)

$0.28 0.00 (-0.29%)
Market Cap 4.61M
Revenue (ttm) 130,000.00
Net Income (ttm) -13.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,646.15%
Debt to Equity Ratio 0.00
Volume 268,000
Avg Vol 7,097,112
Day's Range N/A - N/A
Shares Out 16.59M
Stochastic %K 25%
Beta 1.45
Analysts Strong Buy
Price Target $64.83

Company Profile

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic c...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 224 1000
Website: vivosim.ai
Address:
11555 Sorrento Valley Road, Suite 100, San Diego, United States
HK_Zhou
HK_Zhou Sep. 8 at 4:36 AM
$VIVS Total scam ...
0 · Reply
HK_Zhou
HK_Zhou Sep. 6 at 1:05 PM
$VIVS Dilution scam !!
0 · Reply
HK_Zhou
HK_Zhou Sep. 6 at 8:29 AM
$VIVS What a bet 2800 dollars....
0 · Reply
HK_Zhou
HK_Zhou Sep. 6 at 8:16 AM
$VIVS Dillution scam , CEO paid almost 1 million... What a joke.
0 · Reply
BigJuanOTC
BigJuanOTC Sep. 4 at 4:28 PM
$VIVS Time for some new momo to kick in
0 · Reply
CowboyCapital1
CowboyCapital1 Sep. 4 at 4:09 PM
$VIVS CCO buys 10,000 shares outside trading plan.
1 · Reply
Fox71
Fox71 Sep. 4 at 3:48 PM
$VIVS no pain no gain
0 · Reply
NewsAndFilings
NewsAndFilings Sep. 4 at 1:40 AM
Microcaps $GPRO, $FLYE, $HKPD, $VIVS https://thestreetreports.com/microcaps-gpro-flye-hkpd-vivs-to-watch-now/
0 · Reply
CowboyCapital1
CowboyCapital1 Sep. 3 at 5:49 PM
$VIVS Break .30c flood gates will open. Insider buying and new drug development. $SPWR $GPRO $CHPT $GIPR
0 · Reply
CowboyCapital1
CowboyCapital1 Sep. 3 at 3:58 PM
$VIVS The pressure in this stock🌡
0 · Reply
Latest News on VIVS
VivoSim Labs to Add Rat Liver Model to NAMkind Platform

Sep 1, 2026, 8:05 AM EDT - 6 days ago

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

VivoSim regains compliance with Nasdaq

2026-08-06T13:56:30.000Z - 4 weeks ago

VivoSim regains compliance with Nasdaq

VivoSim Provides Financial and Listing Compliance Update

Aug 6, 2026, 8:05 AM EDT - 4 weeks ago

VivoSim Provides Financial and Listing Compliance Update

VivoSim files to sell 9.41M shares of common stock for holders

2026-07-31T20:20:26.000Z - 5 weeks ago

VivoSim files to sell 9.41M shares of common stock for holders

VivoSim enters China with first commercial sales of NAMkind testing services

2026-07-21T12:45:19.000Z - 6 weeks ago

VivoSim enters China with first commercial sales of NAMkind testing services

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

Jul 21, 2026, 8:05 AM EDT - 6 weeks ago

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

Jul 16, 2026, 8:30 AM EDT - 7 weeks ago

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

Why Is Penny Stock VivoSim Labs (VIVS) Up Today?

2026-07-15T13:16:57.000Z - 7 weeks ago

Why Is Penny Stock VivoSim Labs (VIVS) Up Today?

LLY

VivoSim receives $5M milestone payment from Eli Lilly

2026-07-15T12:51:36.000Z - 7 weeks ago

VivoSim receives $5M milestone payment from Eli Lilly

LLY

VivoSim sees FY27 revenue up over 500%

2026-07-15T12:51:24.000Z - 7 weeks ago

VivoSim sees FY27 revenue up over 500%

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

Jul 15, 2026, 8:05 AM EDT - 7 weeks ago

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

Jun 29, 2026, 8:05 AM EDT - 2 months ago

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

Apr 28, 2026, 8:05 AM EDT - 4 months ago

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

VivoSim Announces Pricing of up to a $4 Million Public Offering

Apr 1, 2026, 8:05 AM EDT - 5 months ago

VivoSim Announces Pricing of up to a $4 Million Public Offering

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

Mar 24, 2026, 8:05 AM EDT - 5 months ago

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

VivoSim appoints Arumugham Raghunathan as VP, global sales

2026-03-03T13:34:44.000Z - 6 months ago

VivoSim appoints Arumugham Raghunathan as VP, global sales

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

Mar 3, 2026, 8:05 AM EST - 6 months ago

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

VivoSim to debut antibody drug conjugate data at SOT meeting

2026-02-11T13:22:48.000Z - 6 months ago

VivoSim to debut antibody drug conjugate data at SOT meeting

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

Feb 11, 2026, 8:05 AM EST - 6 months ago

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

Jan 29, 2026, 4:05 PM EST - 7 months ago

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

VivoSim appoints Sethi as Chief Scientific Officer

2026-01-06T13:36:13.000Z - 8 months ago

VivoSim appoints Sethi as Chief Scientific Officer

VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

Jan 6, 2026, 8:05 AM EST - 8 months ago

VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

VivoSim appoints Lialin as Chief Commercial Officer

2025-08-14T12:15:09.000Z - 1 year ago

VivoSim appoints Lialin as Chief Commercial Officer

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

Aug 14, 2025, 8:05 AM EDT - 1 year ago

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

May 13, 2025, 8:05 AM EDT - 1 year ago

VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

VivoSim NAMkind platform featured in presentation at DDW

2025-05-07T12:27:34.000Z - 1 year ago

VivoSim NAMkind platform featured in presentation at DDW

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

May 7, 2025, 8:05 AM EDT - 1 year ago

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

Apr 24, 2025, 8:05 AM EDT - 1 year ago

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

VivoSim to Carry Forward Organovo 3D Bioprinting

Apr 23, 2025, 8:05 AM EDT - 1 year ago

VivoSim to Carry Forward Organovo 3D Bioprinting

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

Apr 2, 2025, 8:05 AM EDT - 1 year ago

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

Organovo Provides Business Update

Mar 27, 2025, 8:05 AM EDT - 1 year ago

Organovo Provides Business Update

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Mar 25, 2025, 11:25 AM EDT - 1 year ago

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

LLY

Organovo Announces Reverse Stock Split

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Organovo Announces Reverse Stock Split

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

GRCE MTNB

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Mar 6, 2025, 8:05 AM EST - 1 year ago

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Feb 25, 2025, 8:05 AM EST - 1 year ago

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Jan 6, 2025, 8:05 AM EST - 1 year ago

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Nov 20, 2024, 8:05 AM EST - 1 year ago

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Nov 13, 2024, 8:06 AM EST - 1 year ago

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Jul 16, 2024, 8:05 AM EDT - 2 years ago

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

May 21, 2024, 8:05 AM EDT - 2 years ago

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

May 14, 2024, 11:00 AM EDT - 2 years ago

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

May 8, 2024, 8:00 PM EDT - 2 years ago

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Organovo's fatty liver disease drug meets main goal in mid-stage study

Apr 15, 2024, 8:28 AM EDT - 2 years ago

Organovo's fatty liver disease drug meets main goal in mid-stage study

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Apr 15, 2024, 8:05 AM EDT - 2 years ago

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

Jan 25, 2024, 8:05 AM EST - 2 years ago

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

Jan 9, 2024, 8:05 AM EST - 2 years ago

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

Dec 6, 2023, 8:05 AM EST - 2 years ago

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

Nov 13, 2023, 8:05 AM EST - 2 years ago

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

Organovo Highlights FXR314 Combination Therapy Potential and Plan

Nov 8, 2023, 8:05 AM EST - 2 years ago

Organovo Highlights FXR314 Combination Therapy Potential and Plan

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Sep 8, 2023, 12:46 PM EDT - 3 years ago

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Aug 23, 2023, 8:05 AM EDT - 3 years ago

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Announces FXR Program

Mar 21, 2023, 8:05 AM EDT - 3 years ago

Organovo Announces FXR Program

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

Nov 15, 2022, 8:05 AM EST - 3 years ago

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:20 AM EDT - 4 years ago

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Organovo Announces Postponement of Annual Meeting of Stockholders

Sep 6, 2022, 8:05 AM EDT - 4 years ago

Organovo Announces Postponement of Annual Meeting of Stockholders

Organovo Achieves 3D Tissue Model for Crohn's Disease

May 17, 2022, 8:05 AM EDT - 4 years ago

Organovo Achieves 3D Tissue Model for Crohn's Disease

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Mar 1, 2022, 8:05 AM EST - 4 years ago

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Feb 23, 2022, 8:05 AM EST - 4 years ago

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2022, 4:00 PM EST - 4 years ago

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

Feb 18, 2022, 1:00 PM EST - 4 years ago

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

HK_Zhou
HK_Zhou Sep. 8 at 4:36 AM
$VIVS Total scam ...
0 · Reply
HK_Zhou
HK_Zhou Sep. 6 at 1:05 PM
$VIVS Dilution scam !!
0 · Reply
HK_Zhou
HK_Zhou Sep. 6 at 8:29 AM
$VIVS What a bet 2800 dollars....
0 · Reply
HK_Zhou
HK_Zhou Sep. 6 at 8:16 AM
$VIVS Dillution scam , CEO paid almost 1 million... What a joke.
0 · Reply
BigJuanOTC
BigJuanOTC Sep. 4 at 4:28 PM
$VIVS Time for some new momo to kick in
0 · Reply
CowboyCapital1
CowboyCapital1 Sep. 4 at 4:09 PM
$VIVS CCO buys 10,000 shares outside trading plan.
1 · Reply
Fox71
Fox71 Sep. 4 at 3:48 PM
$VIVS no pain no gain
0 · Reply
NewsAndFilings
NewsAndFilings Sep. 4 at 1:40 AM
Microcaps $GPRO, $FLYE, $HKPD, $VIVS https://thestreetreports.com/microcaps-gpro-flye-hkpd-vivs-to-watch-now/
0 · Reply
CowboyCapital1
CowboyCapital1 Sep. 3 at 5:49 PM
$VIVS Break .30c flood gates will open. Insider buying and new drug development. $SPWR $GPRO $CHPT $GIPR
0 · Reply
CowboyCapital1
CowboyCapital1 Sep. 3 at 3:58 PM
$VIVS The pressure in this stock🌡
0 · Reply
Staker58
Staker58 Sep. 3 at 2:24 PM
$VIVS paddles paddles On life support
0 · Reply
NewsAndFilings
NewsAndFilings Sep. 3 at 12:51 AM
Yesterday's Recap: $BCBC Reports Second Quarter Revenue and Raises Full-Year 2026 Revenue Outlook $UGIZ Signs Letter of Intent to Acquire Unique Global Innovative Solutions Corporation $VIVS to Add Rat Liver Model to NAMkind Platform
0 · Reply
CowboyCapital1
CowboyCapital1 Sep. 2 at 8:04 PM
$VIVS Let's go baby 🎂🍰🥞
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Sep. 2 at 1:19 PM
$VIVS RAT LIVER you say -which rat?
1 · Reply
NewsAndFilings
NewsAndFilings Sep. 2 at 1:38 AM
$VIVS VivoSim Labs to Add Rat Liver Model to NAMkind Platform https://www.globenewswire.com/news-release/2026/09/01/3354127/37000/en/vivosim-labs-to-add-rat-liver-model-to-namkind-platform.html
0 · Reply
CowboyCapital1
CowboyCapital1 Sep. 2 at 12:36 AM
$VIVS zero available shares to short
0 · Reply
Zackpedia
Zackpedia Sep. 1 at 11:41 PM
$VIVS Down to .27, you could’ve sold when I alerted.
0 · Reply
VonDooom
VonDooom Sep. 1 at 10:01 PM
$VIVS Distribution deals in South Korea and China previously triggered major buying interest..
1 · Reply
REDBARN1999
REDBARN1999 Sep. 1 at 8:11 PM
$VIVS CCO just bought 10K shares,I think more insiders will start buying could be a sign of things to come.
2 · Reply
CowboyCapital1
CowboyCapital1 Sep. 1 at 8:09 PM
$VIVS Let's go! Tony Serge believes in it. 10K shares bought.
1 · Reply
CowboyCapital1
CowboyCapital1 Sep. 1 at 2:58 PM
$VIVS We might see something here building something useful Here’s why 🔹 Expanding the platform Just announced plans to develop a **rat liver model** 🔹 Complements their existing **NAMkind human liver platform** 🔹 Broader toxicology offering Gives pharma more tools under one roof 🔹 More capabilities = more contracts Higher value for customers who still use traditional models They’re building a full suite, not just one product. $GPRO $LIDR $RITR $HKPD
1 · Reply
RetiredOldGeezer
RetiredOldGeezer Sep. 1 at 1:52 PM
$VIVS Question is - does Lilly value a feature that they are adding? If Lilly does not care - save your money and focus on milestones not research papers - you do not work for a federal agency or college with unlimited dollars.
0 · Reply